HispanicBusiness

"This potential vaccine tested in patients with Stage IV glioblastoma is designed to leverage the patient's own immune system after surgery and chemo-radiation treatments to hunt and destroy remaining brain tumor cancer cells -- one of the clinical trial testing sites for the experimental vaccine. Previous Phase I study results show the vaccine may improve patient survival by enabling them to remain disease-free longer when the vaccine is combined with standard treatments. I look forward to seeing the Phase II results."

On IMUC's chart, the relative Strength Index (RSI) has turned bullish. The Moving Average Convergence/Divergence has also turned bullish. It appears that Immuno may be close to breaking out, and additional buy-side volume could take the stock to near the $2.65 level, perhaps even higher to the $2.80 range. In yesterday's trading session, the stock filled a gap around $2.40. With the company's near term catalyst approaching shortly, we see ImmunoCellular Therapeutics offering good upside potential.

Immune therapies could end up being the next standard for cancer treatments, so ImmunoCellular Therapeutics is one to keep a close eye on.

Sarepta Therapeutics

Everyone has been watching Sarepta very closely ever since the company reported promising data late last year for its drug Eteplirsen, which is in Phase II clinical stage for the treatment of Duchenne Muscular Dystrophy (DMD), which caused the stock to massively rally from around finance.yahoo.com%2fq%2fhp%3fs%3dSRPT%26d%3d1%26e%3d5%26f%3d2013%26g%3dd%26a%3d5%26b%3d4%26c%3d1997%26z%3d66%26y%3d66">$14 a share to a parabolic price of $45 in one trading session!

The company is hoping to gain accelerated approval for the drug by the FDA this year. According to The Street's biotech reporter Adam Feuerestein:

"It's reasonable to assume FDA will convene an advisory panel to review Eteplirsen if the agency allows Sarepta Therapeutics (SRPT) to file for accelerated approval. I'd say a panel is a near certainty, given the novel exon-skipping mechanism of Eteplirsen and the lingering controversy over the small number of Duchenne muscular dystrophy patients with the drug to date.

"I don't see an Eteplirsen advisory panel as a negative. In fact, I'd wager that a panel would bolster the drug's chances of being approved early. The convincing efficacy and safety data generated already, coupled with powerful patient testimony, would make it extremely difficult for any expert sitting on the panel to vote against eteplirsen.